Ireland· IE-PA-PA1436/049/002
Ticagrelor Bluefish 90 mg film-coated tablets
A ticagrelor product containing ticagrelor, registered in Ireland by Bluefish Pharmaceuticals AB. The same ATC class is registered in 18 of our 19 countries.
Checked against HPRA (Ireland) on
Informational only — not a medical device.
Where it is registered
Ticagrelor is registered in 18 of 19 countries.
Countries holding a registration under ATC B01AC24 (ticagrelor), each read from that country’s own register.
- This record: Ireland, from HPRA (Ireland)
- 10 of them publish a price we can compare per daily dose
Ticagrelor · ATC B01AC24
18 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Germany
- Icelandprice
- Ireland
- Italyprice
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Sweden
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of ticagrelor costs, country by country.
Normalised to the WHO defined daily dose (0.18 g), the median price runs from $0.68 in United States to $1.97 in Spain — a ×2.9 gap.
- 5 markets with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
- US figures are pharmacy acquisition cost (CMS NADAC), not retail
Ticagrelor · price per daily dose (0.18 g)
USD · FX 28 Sept 2026
- ES Spain$1.97
- CH Switzerland$1.80
- IT Italy$0.94
- FR France$0.77
- US United States$0.68 (acquisition cost)
The record
At a glance
HPRA (Ireland)- Active substance
- Ticagrelor
- Manufacturer
- Bluefish Pharmaceuticals AB
- Country
- Ireland (IE)
- ATC code
- B01AC24
- ATC class
- Ticagrelor
- Defined daily dose
- 0.18 g, O
- Reimbursed
- Not published by this register
- Source register
- HPRA (Ireland)
- Last checked
- September 28, 2026
Packs & prices · 1
- ie_pa_numberPA1436/049/002
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
529 interactions on record for ticagrelor.
Graded by severity as the source publishes them — 76 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Ticagrelor · interactions on record
529 records
- 76 severe
- 354 moderate
- 60 minor
Most severe, free to view
- LonafarnibA16AX20severe
- DalteparinB01AB04severe
- EnoxaparinB01AB05severe
- DanaparoidB01AB09severe
39 more interactions with mechanism and management, from a commercially licensed source.
Sign in to check- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same class
Other records under B01AC24
Ticagrelor, as other registers publish it.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of HPRA (Ireland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/e2b10434-6f6b-4c32-b556-bce437f9642f GET /v1/drugs/e2b10434-6f6b-4c32-b556-bce437f9642f?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Film-coated tablet",
"routes": [
"Oral use"
],
"source": "hpra",
"atc_all": [
"B01AC24"
],
"strength": null,
"pa_number": "PA1436/049/002",
"substances": [
"Ticagrelor"
],
"legal_basis": "Generic application (Article 10(1) of Directive No 2001/83/EC)",
"market_info": "Not marketed",
"authorised_at": "17/04/2025",
"dispensing_status": "Product subject to prescription which may be renewed (B)",
"registration_status": "AU",
"supply_legal_status": "Supply through pharmacies only",
"interchangeable_code": "IC0193-166-003"
}See everything about ticagrelor.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.